Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL723767 | 0.82 | PIK3CD (0.56) | MAPTSMN1; SMN2ALDH1A1KDM4EGAA | |
| SCHEMBL724650 | 0.82 | MAPT (0.53) | MAPTSMN1; SMN2ALDH1A1KDM4EGAA | |
| SCHEMBL15348861 | 0.76 | PIK3CD (0.52) | MAPTSMN1; SMN2ALDH1A1KDM4EGAA | |
| SCHEMBL28064462 | 0.75 | PIK3CD (0.48) | MAPTSMN1; SMN2ALDH1A1KDM4EGAA | |
| SCHEMBL15356842 | 0.75 | ALDH1A1 (0.48) | MAPTSMN1; SMN2ALDH1A1KDM4EGAA | |
| SCHEMBL15349131 | 0.73 | AR (0.50) | MAPTSMN1; SMN2ALDH1A1KDM4EGAA | |
| SCHEMBL24829791 | 0.72 | ALDH1A1 (1.00) | MAPTSMN1; SMN2ALDH1A1KDM4EGAA | |
| SCHEMBL19034738 | 0.72 | PIK3CA (0.54) | MAPTSMN1; SMN2ALDH1A1KDM4EGAA | |
| SCHEMBL15348889 | 0.72 | PIK3CD (0.45) | MAPTSMN1; SMN2ALDH1A1KDM4EGAA | |
| SCHEMBL27191747 | 0.72 | MAPT (0.51) | MAPTSMN1; SMN2ALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2432321-B1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2017-06-14 | — | — | EP | disclosed |
| US-9676732-B2 | Ethynyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-06-13 | — | — | US | disclosed |
| EP-3049409-B1 | ETHYNYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-05-03 | — | — | EP | disclosed |
| US-20170114028-A1 | ETHYNYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-04-27 | — | — | US | disclosed |
| EP-3049409-A1 | ETHYNYL DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-08-03 | — | — | EP | disclosed |
| US-20160207890-A1 | ETHYNYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-07-21 | — | — | US | disclosed |
| WO-2015044075-A1 | ETHYNYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-02 | — | — | WO | disclosed |
| US-8410095-B2 | Thiazolopyrimidinone derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-04-02 | — | — | US | disclosed |
| EP-2432321-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20120053147-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-03-01 | — | — | US | disclosed |
| WO-2010135504-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20090062258-A1 | FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1847541-A1 | FUSED PYRIMIDINE DERIVATIVE AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207890-A1 | ETHYNYL DERIVATIVES | GRM2, GRIA4, GRM4 | MAPT 2412/4885SMN1; SMN2 1192/4885ALDH1A1 1383/4885 |
| US-20090062258-A1 | FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | GNRHR, FSHR, NPY4R | MAPT 4612/4885SMN1; SMN2 3274/4885ALDH1A1 4008/4885 |
| US-20120053147-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PIK3CA, PI4KA | MAPT 3699/4885SMN1; SMN2 4638/4885ALDH1A1 2476/4885 |
| US-20170114028-A1 | ETHYNYL DERIVATIVES | GRM2, GRIA4, GRM4 | MAPT 2412/4885SMN1; SMN2 1192/4885ALDH1A1 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.